Kedir Negesso Tukeni

Dilated cardiomyopathy (DCM) is a significant cause of heart failure in younger adults, characterized by left and/or right ventricular dilation and systolic dysfunction, with genetic mutations identified in about 35% of cases. A specific subtype, peripartum cardiomyopathy (PPCM), has been linked to high levels of prolactin and its 16kDa fragment, which contribute to endothelial damage and cardiomyocyte dysfunction. Bromocriptine has shown promise as a treatment for PPCM in placebo-controlled studies, but the variability of prolactin levels during menstrual cycles raises questions about its broader applicability. This study aims to evaluate the effects of bromocriptine on dilated cardiomyopathy in women of reproductive age.